ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer’s disease …
Cowen analyst Ritu Baral is out with a research report on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after conducting separate surveys of 25 …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the initiation of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with major …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is anticipated to announce data from the Phase 2 trial of pimavanserin in Alzheimer’s Disease Psychosis (ADP) come December.
By Brett Eversole U.S.
Insiders sell stock to diversify assets and is highly regulated and scrutinized. Insiders can only sell shares at certain times during the year, and …
Analysts are coming to the biotech round table circling the sidelines on Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Teva Pharmaceutical …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the initiation of ADVANCE, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with negative …
Tazeen Ahmad at Merrill Lynch, one of Wall Street’s best performing analysts, is out with newly bullish insights on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) while …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the third quarter ended September 30, 2016.
